Quest Diagnostics/$DGX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Quest Diagnostics

Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Ticker

$DGX

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

50,500

ISIN

US74834L1008

DGX Metrics

BasicAdvanced
$20B
22.59
$7.91
0.78
$3.05
1.79%

What the Analysts think about DGX

Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.

Bulls say / Bears say

Quest Diagnostics raised its 2024 profit and revenue forecasts due to strong demand for diagnostic tests, with adjusted profit now expected between $8.72 and $8.97 per share, up from the previous $8.60 to $8.90 per share. (reuters.com)
The company completed the acquisition of Canada's LifeLabs for approximately $985 million, expected to contribute about $710 million in annual revenues, expanding its market presence in North America. (reuters.com)
Quest Diagnostics reported a 14.5% increase in fourth-quarter revenues to $2.62 billion and a 6.7% rise in full-year revenues to $9.87 billion for 2024, indicating strong financial performance. (gurufocus.com)
The company faces intense competition from LabCorp and other commercial laboratories, which could pressure pricing and market share. (nasdaq.com)
Quest Diagnostics reported a 7.7% decline in net revenues for the third quarter of 2023 compared to the same period in 2022, indicating potential challenges in maintaining revenue growth. (stockhouse.com)
The company has a significant long-term debt of $3.82 billion as of the second quarter of 2024, with cash and cash equivalents of only $271 million, raising concerns about its liquidity position. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

DGX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DGX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DGX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Jul7
Quest Diagnostics
Dividend·Ex-dividend
Jul21
Quest Diagnostics
Dividend·Payment
$0.80Per share
FAQs